Literature DB >> 9504063

Candida dubliniensis: an emerging opportunistic pathogen.

D Sullivan1, D Coleman.   

Abstract

The incidence of opportunistic fungal infections continues to increase, partly as a result of the continuing AIDS epidemic. Candida albicans remains the most important fungal pathogen and is frequently associated with oral candidiasis in HIV-infected individuals. Over the past decade, however, there has been an increasing number of reports implicating other Candida species, such as C. tropicalis, C. glabrata and C. krusei, in disease in these patients and in other patient groups. During the same period there have also been frequent reports in the literature describing what have generally been termed "atypical" C. albicans strains. These isolates have usually been recovered from symptomatic HIV-infected individuals and are unidentifiable as any recognized Candida species using conventional criteria. Two such groups of isolates recovered from cases of oral candidiasis in Irish and Australian HIV-infected and AIDS patients have been postulated to constitute a novel species which has been termed C. dubliniensis. These isolates are phenotypically very similar to C. albicans in that they produce germ tubes and chlamydospores. However, they have unusual carbohydrate assimilation patterns and grow poorly or not at all at 42 degrees C. Using a variety of DNA fingerprinting techniques and karyotype analysis, the genomic organization of C. dubliniensis was shown to be distinctly different from that of C. albicans. Classification of C. dubliniensis as a separate species was confirmed by phylogenetic analysis, whereby the comparison of ribosomal RNA sequences demonstrated that C. dubliniensis isolates formed a cluster clearly distinct from other Candida species, including C. albicans, to which it is most closely related. Since its original identification, atypical Candida isolates from around the world have been positively identified as belonging to this species. To date, isolates of C. dubliniensis have been recovered mainly from the oral cavities of HIV-infected individuals and are most frequently implicated in cases of recurrent infection following antifungal drug treatment. The clinical importance of this species and the role of drug resistance in its epidemiology have yet to be determined.

Entities:  

Mesh:

Year:  1997        PMID: 9504063

Source DB:  PubMed          Journal:  Curr Top Med Mycol        ISSN: 0177-4204


  30 in total

1.  Retrospective identification and characterization of Candida dubliniensis isolates among Candida albicans clinical laboratory isolates from human immunodeficiency virus (HIV)-infected and non-HIV-infected individuals.

Authors:  M A Jabra-Rizk; W A Falkler; W G Merz; A A Baqui; J I Kelley; T F Meiller
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

Review 2.  Comprehensive analysis of glycosylphosphatidylinositol-anchored proteins in Candida albicans.

Authors:  Mathias L Richard; Armêl Plaine
Journal:  Eukaryot Cell       Date:  2006-12-22

3.  Rapid identification of Candida species in oral rinse solutions by PCR.

Authors:  Giorgio Liguori; Angela Lucariello; Giuseppe Colella; Antonio De Luca; Paolo Marinelli
Journal:  J Clin Pathol       Date:  2007-09       Impact factor: 3.411

4.  Comparison of the hydrophobic properties of Candida albicans and Candida dubliniensis.

Authors:  K C Hazen; J G Wu; J Masuoka
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

5.  Genotypic differences of Candida albicans and C. dubliniensis isolates related to ethnic/racial differences within the same geographic area.

Authors:  Michael J McCullough; Jacks J Jorge; Flavio Lejbkowicz; Eli Lefler; Faris Nassar; Karl V Clemons; David A Stevens
Journal:  Mycopathologia       Date:  2004-07       Impact factor: 2.574

6.  Recognition of Candida albicans Als3 by the germ tube-specific monoclonal antibody 3D9.3.

Authors:  Bertrand Beucher; Agnès Marot-Leblond; Sandrine Billaud-Nail; Soon-Hwan Oh; Lois L Hoyer; Raymond Robert
Journal:  FEMS Immunol Med Microbiol       Date:  2009-04

7.  Candida dubliniensis infections in a pediatric population: retrospective identification from clinical laboratory isolates of Candida albicans.

Authors:  Jean O Kim; Lucille Garofalo; Deborah Blecker-Shelly; Karin L McGowan
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

8.  Replacement of Candida albicans with C. dubliniensis in human immunodeficiency virus-infected patients with oropharyngeal candidiasis treated with fluconazole.

Authors:  Marcos Martinez; José L López-Ribot; William R Kirkpatrick; Brent J Coco; Stefano P Bachmann; Thomas F Patterson
Journal:  J Clin Microbiol       Date:  2002-09       Impact factor: 5.948

9.  Candida dubliniensis candidemia in patients with chemotherapy-induced neutropenia and bone marrow transplantation.

Authors:  J F Meis; M Ruhnke; B E De Pauw; F C Odds; W Siegert; P E Verweij
Journal:  Emerg Infect Dis       Date:  1999 Jan-Feb       Impact factor: 6.883

Review 10.  Fungal biofilms and drug resistance.

Authors:  Mary Ann Jabra-Rizk; William A Falkler; Timothy F Meiller
Journal:  Emerg Infect Dis       Date:  2004-01       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.